Pharmaceutical giant
Pfizer
has tapped
Samsung
Biologics to manufacture products in two deals worth $897 million, the South Korean company said Tuesday.
Pfizer
(ticker: PFE) will look to the biotech arm of the Korean conglomerate Samsung in the period to 2029 to produce biosimilar products, ranging from oncology to immunotherapy, in its new plant in South Korea. Biosimilar drugs are a close copy of an existing approved drug.
Read the full article here